Fitbit receives FDA clearance for passive heart rhythm monitoring to detect signs of atrial fibrillation (AFib) and will roll out the feature in the US soon
The Food and Drug Administration has given Fitbit the green light to monitor users' heart rhythms in the background.
Context & Ripple Effects
Fitbit is following a regulatory path Apple cleared years earlier: after Apple Watch Series 4 brought ECG-based irregular rhythm detection to US wrists in late 2018, and AliveCor's KardiaBand proved the FDA would clear third-party heart accessories for the Apple Watch back in 2017, Fitbit now wins clearance for something different — passive, background rhythm monitoring rather than an on-demand reading.
The move builds on Fitbit's own sensor track record, including its blood oxygen monitoring rollout in early 2020, and lands at a moment when the company needs software-driven differentiation amid low hardware margins ahead of its planned rebrand under Google Health.
First-order effects
- US Fitbit users gain continuous AFib screening without taking an explicit reading, putting Fitbit's wearables in direct feature competition with Apple Watch's irregular rhythm detection at a lower price point.
Second-order effects
- Apple and Samsung face pressure to match always-on rhythm screening rather than on-demand ECGs — a race the FDA itself accelerates by fast-tracking digital health clearances, including later qualifications like Apple's AFib history feature for clinical studies.
Third-order effects
- If passive screening keeps clearing the FDA, consumer wearables consolidate into a two-tier market where health-grade sensor validation, not hardware specs, separates platforms — and the resulting rhythm data becomes an asset for whoever owns the platform, in Fitbit's case Google.
The trend: Wrist-worn devices are shifting from fitness trackers to FDA-cleared passive health screening platforms, with each clearance raising the bar competitors must meet to stay in the category.